This is a summary of the European public assessment report (EPAR) for Brineura. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Brineura. For practical information about using Brineura, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency
Therapeutic Area (MeSH)
N/AATC Code
A16AB
ATC Item
酶类
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| cerliponase alfa | N/A | Cerliponase alfa |
EMA Name
Brineura
Medicine Name
Brineura
Aliases
N/ANo risk management plan link.
